ABVC Biopharma Inc
NASDAQ:ABVC
Intrinsic Value
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. [ Read More ]
The intrinsic value of one ABVC stock under the Base Case scenario is 0.13 USD. Compared to the current market price of 1.48 USD, ABVC Biopharma Inc is Overvalued by 91%.
Valuation Backtest
ABVC Biopharma Inc
Run backtest to discover the historical profit from buying and selling ABVC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ABVC Biopharma Inc
Current Assets | 1.7m |
Cash & Short-Term Investments | 139.5k |
Receivables | 759.6k |
Other Current Assets | 757.7k |
Non-Current Assets | 12.8m |
Long-Term Investments | 2.5m |
PP&E | 8.8m |
Other Non-Current Assets | 1.5m |
Current Liabilities | 5.9m |
Accrued Liabilities | 4.1m |
Short-Term Debt | 899.3k |
Other Current Liabilities | 935k |
Non-Current Liabilities | 172.1k |
Other Non-Current Liabilities | 172.1k |
Earnings Waterfall
ABVC Biopharma Inc
Revenue
|
152.4k
USD
|
Cost of Revenue
|
-302k
USD
|
Gross Profit
|
-149.6k
USD
|
Operating Expenses
|
-8.1m
USD
|
Operating Income
|
-8.2m
USD
|
Other Expenses
|
-2.3m
USD
|
Net Income
|
-10.5m
USD
|
Free Cash Flow Analysis
ABVC Biopharma Inc
ABVC Profitability Score
Profitability Due Diligence
ABVC Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
ABVC Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
ABVC Solvency Score
Solvency Due Diligence
ABVC Biopharma Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
ABVC Biopharma Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABVC Price Targets Summary
ABVC Biopharma Inc
According to Wall Street analysts, the average 1-year price target for ABVC is 2.02 USD .
Ownership
ABVC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ABVC Price
ABVC Biopharma Inc
Average Annual Return | -48.23% |
Standard Deviation of Annual Returns | 39.16% |
Max Drawdown | -100% |
Market Capitalization | 15.6m USD |
Shares Outstanding | 10 560 400 |
Percentage of Shares Shorted | 17.07% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
Contact
IPO
Employees
Officers
The intrinsic value of one ABVC stock under the Base Case scenario is 0.13 USD.
Compared to the current market price of 1.48 USD, ABVC Biopharma Inc is Overvalued by 91%.